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IntroductIon
Renal osteodystrophy is a multifactorial disorder of bone re-
modeling, bone mineralizatyion and/or bone quality (volume 
and structure). It occurs early during the course of chronic 
kidney disease (CKD; in stage 3), as part of CKD-related 
bone and mineral disorder (CKD-MBD) (1, 2). Disturbances 
of bone and mineral metabolism are particularly marked in 
patients undergoing renal replacement therapy and after kid-
ney transplant, and have been associated with an increase 
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AbstrAct
Background: To optimize the noninvasive evaluation of 
bone remodeling, we evaluated, besides routine serum 
markers, serum levels of several cytokines involved in 
bone turnover.
Methods: A transiliac bone biopsy was performed in 47 
hemodialysis patients. Serum levels of intact parathy-
roid hormone (iPTH; 1-84), total alkaline phosphatases 
(tAP), calcium, phosphate and aluminum (Al) were 
measured. Circulating levels of interleukin-6 (IL-6), IL-1 
receptor antagonist (IL-1Ra) and soluble IL-6 recep-
tor (sIL-6r) were determined using ELISA. Circulating 
IL-1β, IL-6, IL-8, IL-10, IL-12p70 and tumor necrosis 
factor-alpha (TNF-α) were simultaneously quantified 
by flow cytometric immunoassay.
Results: Patients with low/normal bone formation rate 
(L/N-BFR) had significantly lower serum iPTH (p<0.001) 
and tAP (p<0.008) and significantly higher Al (p<0.025) 
than patients with high BFR. Serum calcium and phos-
phorus, however, did not differ (p=NS). An iPTH >300 
pg/mL in association with tAP >120 U/L showed low 
sensitivity (58.8%) and low negative predictive value 
(44.0%) for the diagnosis of high BFR disease. An iPTH 
<300 pg/mL in association with normal or low tAP, <120 
U/L, was associated with low sensitivity (66.7%) but 
high specificity (97.1%) for the diagnosis of L/N-BFR. 
Serum IL-1, IL-6, IL-12p70 and TNF-α were positively 
1 Department of Nephrology, Hospital Curry Cabral,  
Lisbon - Portugal 
2University of Antwerp, Antwerp - Belgium 
3Key-Point, Lisbon - Portugal
4 U-845 and Department of Nephrology, Necker Hospital, 
Paris - France
correlated with BFR, serum IL1-Ra and IL-10 with 
bone area, and by multiple regression analysis, tAP 
and IL-6 were independently predictive of BFR.
Conclusions: Significant associations were found 
between several circulating cytokines and bone his-
tomorphometry in dialysis patients. The usefulness 
of these determinations in the noninvasive evalua-
tion of bone remodeling needs to be confirmed in 
larger dialysis populations.
Key words: Bone biopsy, Cytokines, Histomorphom-
etry, Intact parathyroid hormone, Renal Osteodystro-
phy, Total alkaline phosphatases
784
Ferreira et al: Circulating cytokines in renal osteodystrophy
in extraskeletal calcifications, morbidity and mortality (3).
The bone biopsy remains the gold standard in the evalu-
ation of bone remodeling and bone mineralization (4). Ac-
cording to the Kidney Disease Improving Global Outcomes 
(KDIGO) consensus definition, it is proposed that the term 
renal osteodystrophy be used exclusively to define chang-
es in bone morphology (requiring a bone biopsy) observed 
in patients with CKD (1). 
Bone histomorphometry is not used in the majority of CKD 
patients, although it may be of considerable help in the di-
agnosis of patients with atypical or unexplained skeletal fea-
tures. Moreover, it remains of great value for direct measure-
ment of bone turnover and also for research purposes. The 
evaluation of bone turnover (T), bone mineralization (M) and 
bone volume (V), provided by bone biopsy, would represent 
the most useful information for clinical practice (TMV clas-
sification), as proposed by the KDIGO recommendations (1). 
Bone biopsy, an invasive procedure which is not easily ac-
cepted by CKD patients in most countries, gives a picture of 
bone morphology at a given point in time (5). Even though 
it allows the quantification of numerous static and dynamic 
histomorphometric parameters, bone histology should al-
ways be interpreted by the nephrologist in conjunction with 
clinical, biochemical and epidemiological data. The noninva-
sive assessment of bone remodeling using new circulating 
biomarkers is of particular interest in this respect (6). 
Serum parathyroid hormone (PTH) levels have become 
the preferred surrogate measure of bone disease in CKD 
patients. However, it is limited by lack of sensitivity in the 
clinical setting (7, 8), particularly in the diagnosis of low-
turnover bone disease (9). Because it had become appar-
ent that the second-generation PTH assays measuring the 
so-called intact PTH (iPTH) at the same time assessed 
large fragments of the polypeptide (10), novel third-gener-
ation assays have been developed to measure the whole 
PTH molecule alone. The problem with the third-generation 
assays is that they still need to be validated with respect 
to bone histomorphometry (10-12). The currently available 
correlations between serum PTH and bone histomorphom-
etry have all been obtained with second-generation iPTH 
assays. In addition to this major methodological problem, 
the specificity of PTH as an indicator of bone turnover also 
has been questioned by different authors (4, 7, 13, 14). 
In the last few decades, numerous circulating markers of 
bone turnover have been proposed for the noninvasive 
evaluation of bone remodeling. They include serum markers 
of bone formation such as osteocalcin, total alkaline phos-
phatases (tAP), bone-specific alkaline phosphatase (bAP) 
and procollagen type I C-terminal peptide (PICP), as well as 
markers of bone resorption such as pyridinoline, deoxypyri-
dinoline, tartrate-resistant acid phosphatase and procolla-
gen type I C-terminal telopeptide (ICTP) (2, 6, 15, 16).
Some of these humoral markers may be useful in the dis-
crimination between high and normal bone turnover (16-18), 
but their value remains more questionable for the diagnosis 
of adynamic bone disease (18, 19). A higher sensitivity and 
specificity in the noninvasive diagnosis of bone remodel-
ing in CKD patients can be obtained by the combination 
of several of these markers of bone formation and bone 
resorption (6, 13, 17). However, a convincing distinction 
between normal- and low-turnover bone disease is much 
more difficult to achieve in the individual patient, based on 
the use of such noninvasive markers (9, 13, 14). 
In the last few years, several groups of investigators, in-
cluding ourselves, have demonstrated a major role for sev-
eral local and circulating growth factors and cytokines in 
bone metabolism, in particular for the interaction between 
osteoclasts and osteoblasts (20, 21).
To optimize the noninvasive evaluation of bone remodeling, 
we evaluated, in addition to routine serum markers, the cir-
culating levels of a variety of cytokines known to be involved 
in bone turnover. Abnormalities in several of these factors 
are frequently observed in CKD patients (22, 23). The goal of 
the present study was to evaluate the combined assessment 
of conventional serum markers of bone turnover with more 
recently discovered local activators and inhibitors such as 
cytokines and their receptors and antagonists in the nonin-
vasive and sequential evaluation of bone remodeling.
subjects And methods
The present study was performed in 47 white prevalent 
hemodialysis patients, 17 women and 30 men, aged 48.2 
± 15.0 years (mean ± SD), and treated with a standard 
hemodialysis procedure of 3 x 4 hours/week, for a mini-
mum duration of 6 months and a mean duration of 81.0 ± 
52.5 months. None of the patients was diabetic, presented 
active liver disease or had been treated with steroids or 
bisphosphonates. Thirty-one patients were treated with 
calcitriol. The primary causes of CKD stage 5 were hyper-
tension (n=12), glomerulonephritis (n=10), pyelonephritis 
(n=6), polycystic kidneys (n=5), interstitial nephrosis (n=5) 
and other (n=9). Patients were dialyzed with high-flux poly-
sulphone dialyzer and volumetric monitors. Ultrapure water 
was used, and endotoxin levels were checked by the chro-
mogenic kinetic limulus amebocyte lysate (LAL) method.
All patients who had undergone a bone biopsy at our insti-
tution during a time period of 24 months were included in 
the study. The bone biopsies were performed based on re-
quests by the treating nephrologists for a precise diagnosis 
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of the underlying osteopathy. The main reasons to perform 
a bone biopsy were a suspicion of aluminum-related bone 
disease or a history of significant aluminum exposure (af-
ter a treatment with aluminum-based phosphate binders), 
the indication of surgical parathyroidectomy (particularly in 
conjunction with previous or ongoing exposure to heavy 
metals such as aluminum or iron), unexplained hypercalce-
mia, severe bone pain and pathological fractures.
Bone biopsies
After informed consent was obtained, a transiliac (5-mm di-
ameter) bone biopsy was performed. Iliac crest bone sam-
ples for mineralized bone histology and histomorphometry 
were fixed with ethanol at room temperature, dehydrated 
and embedded in methylmethacrylate. To measure not only 
static but also dynamic parameters of bone formation, bi-
opsies were taken after double tetracycline administration 
(3 days on, 10 days off, 2 days on). These labels were vi-
sualized on unstained 10-µm sections by fluorescence mi-
croscopy. Sections of 5 µm were stained using the Goldner 
method and histomorphometrically analyzed for static pa-
rameters. Aluminum deposits on trabecular surface and in 
cortical bone were quantified after specific aluminon stain-
ing. A magnification of ×200 was used.
All histomorphometric measurements were performed on 
a KS-400 image analysis system, running custom macro 
programs. To obtain histomorphometric and histodynamic 
measures, an interactive color video-based image analysis 
system was used. 
Results have been reported according to standardized no-
menclature (24). The following variables were measured: bone 
area (B.Ar), osteoid area (O.Ar), osteoid perimeter (O.Pm), 
eroded perimeter (E.Pm) and quiescent perimeter (Q.Pm). 
Double-labeled perimeter (dL.Pm) and total perimeter (tL.
Pm) were measured on unstained sections. Per section, 10-
15 consecutive fields were analyzed. Out of these primary 
measurements, the following derived parameters were cal-
culated: bone area (B.Ar [%]): the area of trabecular bone 
including both mineralized bone and osteoid, expressed as 
a percentage of the total tissue area; osteoid area (O.Ar [%]): 
the measured area of osteoid, expressed as a percentage 
of total B.Ar; osteoid perimeter (O.Pm [%]): trabecular bone 
perimeter occupied by osteoid as a percentage of the total 
bone perimeter; osteoid width (O.Wi [µm]): the mean width 
of surface osteoid seams, calculated by dividing the mea-
sured osteoid area by the length of the osteoid seams; erod-
ed perimeter (E.Pm [%]): the percentage of trabecular bone 
perimeter characterized by the presence of scalloped bone 
resorptive lacunae; double-labeled perimeter (dL.Pm [%]): 
percentage of total endosteal perimeter exhibiting a double 
fluorescent tetracycline label; mineral apposition rate (MAR 
[µm/day]): the rate by which osteoid is mineralized, calculat-
ed as the average distance between midpoints of 2 consec-
utive tetracycline labels, divided by the time interval between 
the labeling periods (10 days); adjusted apposition rate (AjAr 
[µm/day]): mineral apposition rate averaged over the entire 
osteoid perimeter; bone formation rate (BFR [µm2/mm2 per 
day]): area of bone formed per unit of time, with reference to 
tissue area, calculated as the product of mineral apposition 
rate and mineralizing perimeter; the latter is calculated as the 
sum of doubly labeled plus half of singly labeled perimeter 
per bone perimeter; osteoid maturation time (Omt [days]): 
the ratio of osteoid width (O.Wi/MAR, where O.Wi is mea-
sured in µm and MAR in µm/day); and mineralization lag time 
(Mlt [days]): mean interval between deposition and mineral-
ization of any infinitesimal volume of matrix, averaged over 
the entire life span of the osteoid seam.
Patients were divided into 2 groups according to the ac-
cepted criteria for the diagnosis of high bone turnover 
(High BT) or low/normal bone turnover (Low-Norm BT) (25). 
A BFR > 613 µm2/mm2 per day and the presence of fibro-
sis were used to define high-turnover bone disease (25). A 
BFR between 97 and 613 µm2/mm2 per day was consid-
ered normal (25). In 2 patients a diagnosis of normal bone 
turnover was made in the presence of higher BFR, due to 
the absence of fibrosis and the normality of all other static 
and dynamic parameters, underlining the relevance of a 
global evaluation of bone parameters.
The biopsies were examined and classified by 2 indepen-
dent observers who had no knowledge of clinical and bio-
chemical findings.
Serum biochemistry
Blood samples were withdrawn at the same time as the bone 
biopsies, and serum levels of iPTH, tAP, calcium, phosphorus, 
aluminum and circulating cytokines were evaluated. Serum 
iPTH was measured with a commercial immunoradiometric 
assay (Nichols Institute Diagnostics, San Juan Capistrano, 
CA, USA), based on the double antibody technique. The nor-
mal iPTH range with this assay is 10-65 pg/mL. 
Serum phosphorus and total calcium were also deter-
mined by standard automated techniques, with a normal 
range of 3.0-4.5 mg/dL and 8.8-10.5 mg/dL, respectively. 
Serum tAP was measured by a standard automated tech-
nique as well. Normal values were in the range of 35-120 
U/L. Serum levels of aluminum were evaluated by elec-
trothermal atomic absorption spectrometry with Zeeman 
background correction. 
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Serum circulating levels of interleukin-6 (IL-6), interleukin-1 
receptor antagonist (IL-1Ra), and soluble interleukin-6 recep-
tor (sIL-6r) were determined by ELISA (Medgenix). Serum 
interleukin-1β (IL-1β), IL-6, interleukin-8 (IL-8), interleukin-10 
(IL-10); interleukin-12p70 (IL-12p70) and tumor necrosis 
factor-alpha (TNF-α) were simultaneously quantified by flow 
cytometry using Becton Dickinson Cytometric Bead Array 
(BD-CBA) methodology. This flow cytometric immunoassay 
employs a series of particles (beads) with discrete fluores-
cence intensities to simultaneously detect multiple soluble 
analytes such as cytokines. Each bead in the BD-CBA kit pro-
vides a capture surface for a specific cytokine. The mixture 
of BD-CBA beads is in suspension in order to quantify the 
analytes by flow cytometry. The system uses the sensitivity of 
amplified fluorescence detection by flow cytometry to mea-
sure, in a small sample volume, soluble analytes in a particle-
based immunoassay. We used the BD Human Inflammation 
CBA kit to measure the above-mentioned cytokine levels in a 
single sample. The beads with distinct fluorescence intensities 
coated with specific capture antibodies were mixed together 
and detected in the FL3 channel of the flow cytometer. This 
mixture (50 µl/tube) was incubated with diluted recombinant 
standards (50 µl/tube) as test samples (50 µl/tube). After 1.5 
hours of incubation (protected from light), the samples were 
washed with 1 mL wash buffer and centrifuged. The residual 
volume of 100 µL was incubated for 1.5 hours protected from 
light with phycoerythrin (PE)-conjugated antibodies (50 µl/
tube). The tubes were again washed with 1 mL of wash buf-
fer and centrifuged. Wash buffer (300 µL) was added to each 
tube. The samples were acquired with Cell Quest Software in 
a BD FACS Scan. The flow cytometer setup was previously 
completed with FACSComp software in Lyse/No Wash mode 
with BD Calibrite beads. The cytometer setup for the BD-CBA 
was performed using Cytometer Setup Beads,  an FITC Posi-
tive Control Detector and a PE Positive Control Detector to 
adjust the settings for side light scatter (SSC), forward light 
scatter (FSC), threshold, FL1 PMT, FL2 PMT, FL3 PMT and 
compensation settings. The number of events acquired was 
1,800 to ensure that the sample file contained approximately 
300 events per capture bead. Normal levels and limits of de-
tection for cytokines in this cytometric bead array were de-
termined in 8 volunteers (26). The analysis of BD-CBA data 
was optimized using the BD-CBA software, which uses sev-
eral matrices to define the standard curves and quantitative 
results for each cytokine.
Statistical analysis
In descriptive analysis, variables were expressed as me-
dian values with range for continuous parameters and fre-
quencies with percentages for categorical parameters; and 
95% confidence intervals were presented. Comparisons 
between values were made using the Mann-Whitney test. 
Correlations between parameters were evaluated using the 
Spearman correlation. Further, multiple linear regression was 
performed considering in the first block the classical clinical 
parameters that were correlated with BFR, and adding in a 
second block the cytokines which were also correlated. To 
perform this analysis, variables that were not normally dis-
tributed were submitted to a normalization process through 
logarithm application. The method used for variable selec-
tion when modeling BFR was the stepwise method. 
For all analyses performed, a p value of <0.05 was consid-
ered as statistically significant. Statistical analysis was per-
formed using SPSS 15.0 for Windows statistical software.
results
As pointed out above, the 47 patients of the study were 
classified according to their BT, based on BFR. Eleven pa-
tients (23%) were allocated to the Low-Norm BT group (6 
patients presented normal bone and 5 adynamic bone dis-
ease), and 36 patients (77%) to the High BT group.
Biochemical parameters are presented in Table I. The Low-
Norm BT patients had lower serum iPTH and tAP, but higher 
serum aluminum levels than the High BT patients. In fact, the 
need to exclude aluminum overload in mineralization front 
before parathyroidectomy was one of the most frequent rea-
sons for a bone biopsy, as mentioned in the “Methods” sec-
tion. Serum calcium and phosphorus levels were similar in 
the 2 groups. Seven patients had aluminum deposits in more 
than 10% of the trabecular surface (5 in Low-Norm BT group 
and 2 in High BT group), but only 2 of them (1 in each group) 
in more than 50% of the trabecular surface. 
An increase in iPTH (>300 pg/mL) together with a high tAP 
value (>120 U/L) showed a very low sensitivity (58.8%) and 
low negative predictive value (44.0%) for the diagnosis 
of high-turnover bone disease. An iPTH level below 300 
pg/mL in association with normal or low serum tAP (<120 
U/L) was associated with a low sensitivity (66.7%) but high 
specificity (97.1%) for the diagnosis of Low-Norm BT. 
Bone histomorphometric and histodynamic data are pre-
sented in Table II. High BT patients had significantly higher 
osteoid area and osteoid perimeter than Low-Norm BT pa-
tients, reflecting an increase in bone formation, but without 
significant impairment of mineralization. Osteoid width was 
also increased in this group, but clearly below the osteomal-
acia threshold. High resorption activity was illustrated by a 
marked increase in eroded perimeter, as observed in the 
High BT patients. In addition to BFR, the other dynamic 
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TABLE I 
BIOCHEMISTRY DATA ACCORDING TO BONE TURNOVER GROUP
Serum parameters
Low-normal bone turnover 
group (n=11)
































All values are expressed as median (range).  
Al = serum aluminum; Ca = serum calcium; iPTH = intact parathyroid hormone; NS = not significant; P = serum phosphorus; 
tAP = total alkaline phosphatases.
TABLE II  
BONE HISTOMORPHOMETRY DATA ACCORDING TO BONE TURNOVER GROUP
Bone parameters
Low-normal bone turnover 
group 
(n=11)
High bone turnover group 
(n=36)
p Value
B.Ar, % 18.7 (12.4-25.2) 20.2 (10.2-45.4) NS
O.Ar, % 1.2 (0.2-38.2) 5.0 (0.5-27.8) <0.001
O.Wi, µm 6.3 (4-47.0) 8.9 (5.0-26.1) <0.001
O.Pm, % 17.8 (2.9-90.7) 38.6 (7.1-72.9) 0.001
E.Pm, % 2.0 (0-4.9) 11.5 (4.5-27.5) <0.001
dL.Pm, % 6.2 (1.4-16.7) 23.0 (8.5-44.7) <0.001
MAR, µm/day 1.5 (0.6-2.0) 1.9 (1.1-4.2) 0.03
AjAr, µm/day 0.7 (0.4-1.5) 2.0 (0.5-10.1) <0.001
BFR, µm2/mm2 per day 245 (69.1-763.6) 1750 (792.0-6420.7) <0.001
Mlt, days 6.9 (4.3-20.2) 5.4 (0.5-32.0) NS
Omt, days 4.2 (2.3-11.6) 4.5 (1.6-12.6) NS
All values are expressed as median (range). 
B.Ar = bone area; O.Ar = osteoid area; O.Wi = osteoid width; O.Pm = osteoid perimeter; E.Pm = eroded perimeter; dL.Pm = 
double-labeled perimeter; MAR = mineral apposition rate; AjAr = adjusted apposition rate; BFR = bone formation rate; Mlt = 
mineralization lag time; Omt = osteoid maturation time;  NS = not significant. 
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histomorphometric parameters were also significantly in-
creased in High BT group. In contrast, mineralization lag 
time and osteoid maturation time were normal and simi-
lar in the 2 groups, excluding the presence of a significant 
mineralization defect in these patients. 
Serum cytokine levels are presented in Table III, split into 
2 groups according to the rate of bone turnover. Serum 
IL-1β, IL-1Ra, IL-6, sIL-6r, IL-8, IL-10, IL-12p70 and TNF-α 
concentrations did not differ. Serum calcium, aluminum, IL-
10 and IL-1Ra correlated negatively with bone area (B.Ar). 
Serum tAP correlated positively with osteoid area (O.Ar), 
osteoid perimeter (O.Pm), BFR and mineralization lag time 
(Mlt). Serum iPTH also presented highly significant correla-
tions with static (O.Pm and E.Pm) and dynamic (BFR) pa-
rameters of bone formation and bone resorption (Tab. IV).
Concerning the relation between BFR and routine se-
rum parameters, iPTH and tAP were the only parameters 
that showed a positive correlation (ρ=0.55, p<0.001; and 
ρ=0.51, p=0.001, respectively) (Tab. V). These parameters 
contributed in a statistical manner to explain BFR changes, 
according to multiple linear regression coefficients (Tab. 
VI). When adding to the model the cytokine parameters that 
were correlated with BFR, namely IL-6, IL-12p70, TNF-α 
and IL-1beta, the model estimated to explain BFR varia-
tions included only tAP and IL-6 (Tab. VI).
dIscussIon
Despite considerable recent advances in our knowledge 
of mineral metabolism disturbances and therapeutic mo-
dalities, CKD-MBD with its skeletal expression of renal 
osteodystrophy remains 1 of the most disturbing com-
plications in chronic dialysis patients, and also in kidney 
transplant recipients.
Bone histology remains the gold standard for the diagno-
sis of renal osteodystrophy. A clear distinction between 
TABLE III  














IL-1β, pg/mL 9.6 (0-27.5) 8.6 (0-810) NS <48 7.2-5,000
IL-1Ra, pg/mL 541 (184-935) 259 (16-2322) NS <260 8-5,000
IL-6, pg/mL 3.3 (0-51.7) 2.0 (0-68.8) NS <5.6 3-5,000
sIL-6r, pg/mL 76.5 (57.0-113) 74 (42.0-428) NS <80 16-5,000
IL-8, pg/mL 17.5 (9.7-29.4) 16.3 (6.4-69.6) NS <40 3.6-5,000
IL-10, pg/mL 3.8 (0-13.8) 1.5 (0-20.4) NS <3.7 2.8-5,000
IL-12p70, pg/mL 2.6 (0-8.0) 4.0 (0-172.4) NS <9.4 1.9-5,000
TNF-α, pg/mL 0.9 (0-4.5) 2.0 (0-26.0) NS <3.7 2.8-5,000
All values are expressed as median (range). Normal levels and limits of detection according to reference (26).  
IL-1β = serum interleukin-1β; IL-1Ra = interleukin-1 receptor antagonist; IL-6 = interleukin-6; sIL-6r = soluble interleukin-6 
receptor; IL-8 = interleukin-8; IL-10 = interleukin-10; IL-12p70 = interleukin-12p70; TNF-α = tumor necrosis factor-alpha; NS = 
not significant.
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high, normal and low bone turnover disease, and a precise 
evaluation of bone mineralization in uremic patients still re-
quires the invasive and expensive technique of bone histo-
morphometry, which includes the assessment of static and 
kinetic variables after double tetracycline labeling (1, 27). 
Precise knowledge of the underlying bone disease would 
allow, at least theoretically, a more appropriate treatment 
approach than that based solely on presently available se-
rum markers of bone turnover (5).
In recent years, a variety of circulating biochemical mark-
ers of bone turnover have been tested and used with the 
purpose of evaluating bone remodeling in uremic patients in 
the absence of bone biopsy. Used individually or in associa-
tion with other methods, these biomarkers should allow the 
nephrologist to improve the diagnosis of renal osteodystro-
phy in CKD patients (6, 14, 15). This is all the more necessary 
since the number of centers with expertise in bone histomor-
phometry has progressively decreased. Moreover, the infor-
mation provided by bone biopsy (which gives a snapshot of 
bone lesions) may be significantly increased by the combi-
nation with bone remodeling serum marker levels.
Recently, we have shown in a population of 119 hemodi-
alysis patients treated according to the Kidney Disease 
Outcomes Quality Initiative (K/DOQI) guidelines and sub-
mitted to a bone biopsy, that adynamic bone disease was 
the most frequent abnormality (59%). Interestingly, serum 
iPTH was in the normal or high K/DOQI guideline range in 
more than one third of the patients with low bone turnover 
(28). A burning question in clinical practice therefore is how 
the precise diagnosis of a given type of renal osteodystro-
TABLE IV  




















O.Ar, % -0.3 (<0.036) -0.3 (<0.025) +0.7 (<0.001)
O.Pm, % -0.4 (<0.009) +0.6 (<0.001) +0.4 (<0.003)
E.Pm, % +0.6 (<0.001)
Mlt, days +0.3 (<0.048)
Al = serum aluminum; B.Ar = bone area; Ca = serum calcium; E.Pm = eroded perimeter; iPTH = intact parathyroid hormone; Mlt 
= mineralization lag time; NS = not significant; O.Ar = osteoid area; O.Pm = osteoid perimeter; P = serum phosphorus; tAP = 
total alkaline phosphatases.
TABLE V  
CORRELATIONS WITH BONE FORMATION RATE (BFR)
Serum parameters ρ (correlation) p Value
Ca (mg/dL) -0.165 0.162
P (mg/dL) 0.087 0.301
Al (µg/L( -0.251 0.064
iPTH (pg/mL) 0.550 <0.001*
tAP (U/L) 0.505 0.001*
IL-6 (pg/mL) 0.334 0.038*
sIL-6r (pg/mL) 0.254 0.092
IL-Ra (pg/mL) -0.079 0.341
IL-12p70 (pg/mL) 0.358 0.028*
TNF alfa (pg/mL) 0.331 0.040*
IL-10 (pg/mL) -0.095 0.312
IL-1β (pg/mL) 0.332 0.039*
IL-8 (pg/mL) 0.130 0.251
Ca = calcium; P = phosphorus; Al = aluminum; iPTH = intact 
parathyroid hormone; tAP = total alkaline phosphatases;  
IL-6 = interleukin-6; sIL-6r = soluble interleukin-6 receptor;  
IL-1Ra = interleukin-1 receptor antagonist; IL-12p70 = 
interleukin-12p70; TNF-α = tumor necrosis factor-alpha; 
 IL-10 = interleukin-10; IL-1β = serum interleukin-1β; and  
IL-8 = interleukin-8.  
*Statistically significant.
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phy can be reached without performing a bone biopsy, yet 
providing the patient with the best possible treatment to 
maintain optimal bone structure and function. 
The normal remodeling cycle requires that bone resorp-
tion and bone formation take place in a synchronized way, 
which in turn depends on the systematic development and 
activation of osteoclasts and osteoblasts, respectively. Os-
teoclasts originate from hematopoietic granulocyte-mac-
rophage colony-forming units, whereas osteoblasts origi-
nate from pluripotential mesenchymal stem cells (29).
Recently, there has been a remarkable improvement in our 
understanding of the complex biology of bone, with the dem-
onstration of the important role played by a multitude of local 
and circulating growth factors and cytokines (30). The results 
of a small number of studies support the hypothesis that the 
cytokine/cytokine-receptor/receptor antagonist network plays 
a major role in the pathogenesis of renal osteodystrophy (31, 
32), and that the serum levels of some of these local media-
tors might well reflect bone cell activity (33-36). 
Activation of the bone remodeling cycle (activation of osteo-
blasts) appears to be influenced by high levels of IL-1, such 
as the ones reported in dialysis patients (37). Similarly, high 
levels of IL-1 receptor antagonist, which are thought to op-
pose the effects of IL-1, have been detected in these patients 
by our group (20). We found an inverse relationship between 
IL-1 receptor antagonist and osteoblast surface, suggesting 
that a high serum concentration of the IL-1 receptor antago-
nist makes the skeleton relatively insensitive to circulating 
IL-1. On the other hand, at low serum concentration, the 
IL-1 receptor antagonist would allow the cytokine to fully ex-
ert itself in the stimulation of bone formation. In the present 
study, a negative correlation between IL-1Ra and bone area 
(B.Ar) was found, in accord with our previous results and the 
role of this cytokine in osteoblast activation. 
Elevated serum levels of IL-6 have also been reported in di-
alysis patients, as well as in predialysis patients. Montalban 
et al found a correlation between serum IL-6 and bone re-
modeling markers in patients with renal osteodystrophy (38). 
The presence of high serum levels of IL-6 and IL-6 soluble 
receptor has been repeatedly observed in chronic hemodi-
alysis patients, and our group has reported an inverse rela-
tionship between the soluble IL-6 receptor to IL-6 ratio and 
osteoclast surface (20). These findings are in line with the 
role of IL-6 in the promotion of osteoclast differentiation, 
development and activity, as reported by several research 
groups during the last few years, both in studies performed 
in vitro and those performed in vivo (21, 38-41). Some of 
these effects seem to be mediated through the osteoprote-
gerin/receptor activator of nuclear factor-kB (RANK) ligand/
RANK system (40). Our present results also show that IL-6 
serum levels are positively correlated with BFR. 
Interestingly, in multiple linear regression analysis, IL-6 serum 
levels were independently predictive of BFR. In our opinion, 
these results are particularly relevant, as IL-6 is a highly sta-
ble cytokine, with recognized systemic effects (38, 40).
In the present study, serum IL-10 levels correlated nega-
tively with bone area (B.Ar). IL-10 is produced by mono-
cytes, macrophages, B cells and T cells. It inhibits the 
production of several proinflammatory cytokines, includ-
ing IL-1, and thereby interferes with osteoblast stimulation 
(42). This action could be the mechanism underlying the 
observed reduction in bone area, but this hypothesis re-
quires further investigation.
IL-12 is a proinflammatory cytokine produced by mono-
cytes/macrophages, B cells and dendritic cells. It enhances 
myelopoiesis of primitive bone marrow progenitor cells and 
TABLE VI  
MULTIPLE LINEAR REGRESSION COEFFICIENTS
Model 1 Estimated coefficients 95% confidence interval p Value
iPTH (pg/mL) 0.794 (0.289-1.299) 0.003
tAP (U/L) 1.366 (0.339-2.393) 0.011
Model 2
tAP (U/L) 1.622 (0.987-2.256) <0.001
IL-6 (pg/mL) 1.377 (0.253-2.501) 0.018
iPTH = intact parathyroid hormone; tAP = total alkaline phosphatases; IL-6 = interleukin-6.
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synergizes other cytokines to stimulate proliferation of rest-
ing cells. Its effects on bone turnover still need to be clari-
fied, but due to its effects on the monocyte/macrophage 
lineage, it probably also affects osteoclast proliferation and 
maturation (43, 44).
Our study presents several limitations, including a relatively 
high aluminum exposition of the cohort evaluated, the use 
of only second-generation intact PTH levels and the ab-
sence of serum vitamin D sterol measurements. The results 
of our study also need to be confirmed in larger patient 
populations, with a better balance between cases having 
high and low bone turnover bone. Interestingly a significant 
mineralization defect was not observed in any of our pa-
tients, excluding osteomalacia associated with aluminum 
intoxication or severe vitamin D deficiency. 
In conclusion, we show that serum IL-1, IL-6, IL-12p70 
and TNF-α are positively correlated with BFR, serum IL1-
Ra and IL-10 with bone area and that serum IL6 is an in-
dependent predictor of BFR, in a population of prevalent 
dialysis patients. The quantification of the serum levels of 
these cytokines through a simple and reproducible flow cy-
tometry method may be relevant for research purposes or 
to complement the classical biochemical markers of bone 
turnover (such as iPTH and tAP). The usefulness of these 
serum cytokine determinations in the noninvasive evalua-
tion of bone remodeling needs to be confirmed in larger 
dialysis populations.
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